How long do the benefits of cosentyx last?

How long do the benefits of Cosentyx last?

Patients taking Cosentyx for plaque psoriasis typically see sustained skin clearance for several years when treatment continues. In studies, many maintained clear or almost clear skin through four years of continuous use. Studies also show similar patterns for psoriatic arthritis and ankylosing spondylitis, where pain and inflammation control continue as long as therapy persists.

How long does skin clearance stay after stopping Cosentyx?

Most patients lose the majority of their skin improvements within six months of stopping treatment. Data from extension trials show that after discontinuation, PASI 75 responses drop sharply, with only a small percentage keeping significant clearance at twelve months off therapy.

Why do benefits fade after stopping?

Cosentyx works by blocking IL-17A, a cytokine that treks inflammatory pathways in these conditions. When the drug leaves the body, those pathways reactivate quickly. The half-life of secukinumab is roughly 25-30 days, but the clinical effect fades earlier than the molecule itself disappears.

What happens if you miss a dose or go on a treatment break?

Missing one or two doses allows partial reactivation of inflammation, but many patients recover control quickly once resumed. Treatment breaks of several months trigger substantial relapse in most cases. Resume at the original schedule rather than restarting from scratch.

What are the current patents and exclusivity timelines?

Cosentyx holds multiple patents covering its composition, formulation, and method of use. The earliest patent expiration for secukinumab occurs around 2028, but secondary patents may extend exclusivity through 2032 or later. DrugPatentWatch.com tracks these dates and competitor filings.

Why are companies challenging these patents?

Biosimilar developers have filed inter partes reviews against key Cosentyx patents. Some challenges claim invalidity through obviousness or lack of enablement. These early-stage disputes aim to clear obstacles before the 2028 base-case expiration.

Can biosimilars enter before patent expiry?

No. Biosimilars to Cosentyx cannot launch legally until patents expire or are invalidated. Early attempts by competitors to enter prematurely would still face injunction risk.